Cover Image
市場調查報告書

Optimum Therapeutics, LLC 產品平台分析

Optimum Therapeutics, LLC - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 321994
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Optimum Therapeutics, LLC 產品平台分析 Optimum Therapeutics, LLC - Product Pipeline Review - 2014
出版日期: 2014年12月24日 內容資訊: 英文 22 Pages
簡介

Optimum Therapeutics, LLC 是總公司設立於美國的癌症研究機關。正在從事關於癌症及藥物遞輸系統的研究開發。

本報告提供Optimum Therapeutics, LLC 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Optimum Therapeutics, LLC 基本資料

  • Optimum Therapeutics, LLC 概要
  • 主要資訊
  • 企業資料

Optimum Therapeutics, LLC :R&D概要

  • 主要的治療範圍

Optimum Therapeutics, LLC :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Optimum Therapeutics, LLC :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Optimum Therapeutics, LLC :藥物簡介

  • suramin hexasodium
  • Paclitaxel CR
  • RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer

Optimum Therapeutics, LLC :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Optimum Therapeutics, LLC :最新的開發平台資訊

Optimum Therapeutics, LLC :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06748CDB

Summary

Global Markets Direct's, 'Optimum Therapeutics, LLC - Product Pipeline Review - 2014', provides an overview of the Optimum Therapeutics, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Optimum Therapeutics, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Optimum Therapeutics, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Optimum Therapeutics, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Optimum Therapeutics, LLC's pipeline products

Reasons to buy

  • Evaluate Optimum Therapeutics, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Optimum Therapeutics, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Optimum Therapeutics, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Optimum Therapeutics, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Optimum Therapeutics, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Optimum Therapeutics, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Optimum Therapeutics, LLC Snapshot
    • Optimum Therapeutics, LLC Overview
    • Key Information
    • Key Facts
  • Optimum Therapeutics, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Optimum Therapeutics, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Optimum Therapeutics, LLC - Pipeline Products Glance
    • Optimum Therapeutics, LLC - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Optimum Therapeutics, LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Optimum Therapeutics, LLC - Drug Profiles
    • suramin hexasodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Paclitaxel CR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Optimum Therapeutics, LLC - Pipeline Analysis
  • Optimum Therapeutics, LLC - Pipeline Products by Target
  • Optimum Therapeutics, LLC - Pipeline Products by Route of Administration
  • Optimum Therapeutics, LLC - Pipeline Products by Molecule Type
  • Optimum Therapeutics, LLC - Pipeline Products by Mechanism of Action
  • Optimum Therapeutics, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Optimum Therapeutics, LLC, Key Information
  • Optimum Therapeutics, LLC, Key Facts
  • Optimum Therapeutics, LLC - Pipeline by Indication, 2014
  • Optimum Therapeutics, LLC - Pipeline by Stage of Development, 2014
  • Optimum Therapeutics, LLC - Monotherapy Products in Pipeline, 2014
  • Optimum Therapeutics, LLC - Phase II, 2014
  • Optimum Therapeutics, LLC - Preclinical, 2014
  • Optimum Therapeutics, LLC - Discovery, 2014
  • Optimum Therapeutics, LLC - Pipeline by Target, 2014
  • Optimum Therapeutics, LLC - Pipeline by Route of Administration, 2014
  • Optimum Therapeutics, LLC - Pipeline by Molecule Type, 2014
  • Optimum Therapeutics, LLC - Pipeline Products by Mechanism of Action, 2014

List of Figures

  • Optimum Therapeutics, LLC - Pipeline by Top 10 Indication, 2014
  • Optimum Therapeutics, LLC - Pipeline by Stage of Development, 2014
  • Optimum Therapeutics, LLC - Monotherapy Products in Pipeline, 2014
  • Optimum Therapeutics, LLC - Pipeline by Top 10 Target, 2014
  • Optimum Therapeutics, LLC - Pipeline by Top 10 Route of Administration, 2014
  • Optimum Therapeutics, LLC - Pipeline by Top 10 Molecule Type, 2014
  • Optimum Therapeutics, LLC - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top